• CIMERLI^®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS^®** (ranibizumab-injection) for all approved indications
• Acquisition strengthens Sandoz ophthalmology portfolio

Keren Haruvi, President Sandoz North America, said: “I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise. The addition of CIMERLI^® reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the US.”

Sandoz looks forward to providing even more treatment options for US patients with vision impairment and loss. The agreement to acquire the CIMERLI^®* business from Coherus allows us to build a more robust ophthalmic platform that would support future product launches.

Closing is anticipated in 1H 2024, subject to standard conditions and approvals.